8-K: Zevra Therapeutics Announces Third Quarter 2024 Results and Corporate Updates, Highlights FDA Approval of MIPLYFFA

Zevra Therapeutics reports a transformational third quarter, marked by FDA approval of MIPLYFFA, a rare pediatric disease Priority Review Voucher, and a $64.5 million capital raise.

Summary

• Zevra Therapeutics announced its third quarter 2024 financial results and corporate updates, highlighting the FDA approval of MIPLYFFA for Niemann-Pick disease type C (NPC).
• The company received a rare pediatric disease Priority Review Voucher (PRV) following the MIPLYFFA approval.
• As of October 31, 90 prescription enrollment forms for MIPLYFFA were received, with 30% approved for reimbursement.
• OLPRUVA had three new patient enrollments in the third quarter, with reimbursement coverage at approximately 76% of covered lives.
• Zevra completed an End-of-Phase 2 meeting with the FDA for KP1077, and is evaluating strategic alternatives for its development.
• The Phase 3 DiSCOVER trial of celiprolol for Vascular Ehler-Danlos Syndrome (VEDS) has restarted enrollment, with 19 patients now in the trial.
• In August, Zevra completed a public offering of common stock, raising approximately $64.5 million in net proceeds.
• The company has discontinued in-house drug discovery activities and is closing its laboratory facilities.
• Third quarter revenue was $3.7 million, including $2.6 million from the French expanded access program (EAP) for arimoclomol and $1.1 million from the AZSTARYS license agreement.
• The company reported a net loss of $33.2 million, or $0.69 per share, for the third quarter of 2024.
• Cash, cash equivalents, and investments totaled $95.5 million as of September 30, 2024, which is expected to extend the cash runway into 2027.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. The FDA approval of MIPLYFFA and the successful capital raise are positive, but the significant net loss and increased SG&A expenses are concerning. The company's strategic shift and focus on commercialization are promising, but the financial results temper the overall sentiment.

Positives

• FDA approval of MIPLYFFA is a major milestone for the company and the NPC community.
• The rare pediatric disease Priority Review Voucher (PRV) can be monetized to help fund growth.
• The $64.5 million capital raise strengthens the company's financial position.
• The cash runway is expected to extend into 2027, providing financial stability.
• The restart of the Phase 3 DiSCOVER trial for celiprolol is a positive step for the VEDS program.
• The company is refining its commercial strategy for OLPRUVA to focus on specific patient segments.
• The company has a strategic plan for 2025 focused on commercial excellence, pipeline and innovation, talent and culture, and corporate foundation.

Negatives

• The company reported a significant net loss of $33.2 million for the third quarter of 2024.
• Cost of goods sold included a $2.0 million inventory obsolescence reserve expense related to OLPRUVA.
• SG&A expenses increased significantly due to commercial launch activities.
• The company is discontinuing in-house drug discovery activities and closing its laboratory facilities.
• OLPRUVA revenue was de minimis in the third quarter.

Risks

• The company's financial performance is subject to the success of its commercialization efforts for MIPLYFFA and OLPRUVA.
• The company's cash runway is subject to continuing compliance with debt covenants.
• The company's future success depends on the successful development and commercialization of its pipeline programs.
• There are risks associated with the clinical development of KP1077 and celiprolol.
• The company's ability to monetize the PRV is not guaranteed.
• The company is subject to risks associated with the pharmaceutical industry, including regulatory approvals, competition, and pricing pressures.

Future Outlook

The company expects its cash runway to extend into 2027, based on current operating plans, anticipated revenue from MIPLYFFA sales, reimbursements from the French EAP, royalties under the AZSTARYS license agreement, and continued investments into development pipeline programs. This does not include potential proceeds from a PRV sale.

Management Comments

• Neil F. McFarlane, Zevra's President and Chief Executive Officer, stated that the third quarter was one of the most exciting and transformational periods in Zevra's journey.
• Management intends to achieve its goals with a high-performing team committed to execute, focus and innovate to drive continued growth and long-term transformation.

Industry Context

This announcement reflects the ongoing trend of pharmaceutical companies focusing on rare diseases, which often have unmet medical needs and can qualify for orphan drug designations and priority review vouchers. The approval of MIPLYFFA and the company's strategic shift towards commercialization align with this industry trend.

Comparison to Industry Standards

• The approval of MIPLYFFA is a significant achievement, as it is the first FDA-approved drug for NPC, a rare and debilitating disease. This compares favorably to other companies in the rare disease space that are still in the clinical trial phase.
• The company's cash runway extending into 2027 is a positive sign, as many biotech companies struggle with funding. This is comparable to other well-funded companies in the sector.
• The increase in SG&A expenses is expected for a company launching a new product, but the magnitude of the increase is significant and should be monitored. This is a common challenge for companies transitioning from research to commercialization.
• The company's decision to discontinue in-house drug discovery and focus on late-stage development is a common strategy for companies looking to optimize resources and focus on near-term revenue opportunities. This is similar to other companies that have made similar strategic shifts.

Stakeholder Impact

• Shareholders will be impacted by the financial results and the company's strategic decisions.
• Patients with NPC and UCDs will benefit from the availability of MIPLYFFA and OLPRUVA.
• Employees may be affected by the closure of the company's laboratory facilities.
• The company's suppliers and partners will be impacted by the company's commercialization and development activities.

Next Steps

• Zevra will continue to commercialize MIPLYFFA and OLPRUVA.
• The company will evaluate strategic alternatives for the clinical development of KP1077.
• Zevra will continue the Phase 3 DiSCOVER trial of celiprolol.
• The company will present at the Guggenheim Securities Healthcare Innovation Conference on November 13, 2024.
• Zevra will continue to execute its strategic plan for 2025.

Key Dates

Keywords

MIPLYFFA, Niemann-Pick disease type C, NPC, OLPRUVA, Urea Cycle Disorders, UCDs, KP1077, celiprolol, Vascular Ehlers-Danlos Syndrome, VEDS, Priority Review Voucher, PRV, rare diseases, clinical trials, FDA approval, financial results, public offering